Rameda to breathe life into Egyptian IPO market

Egypt’s equity market has been slow to recover to pre-revolution levels, but liquidity is returning and companies are lining up to list.

Cairo-based Rameda Pharmaceuticals is set to price Egypt’s second private-sector initial public offering (IPO) of the year, revitalizing the country’s lacklustre IPO market, which has struggled to recover to pre-revolution levels, despite a healthy pipeline of state and non-state run companies.

Rameda is in the marketing phase of a listing that will value the company in a range of $214 million to $286 million on the Egyptian Exchange (EGX). It could be the largest Egyptian IPO since 2015.

Access this research

Enter your work email address to sign in or check whether your organisation already has access to Euromoney.